Thus, targeted agents including MEK1/2 (an upstream kinase of MAPK), BRAF, and TRK inhibitors have been evaluated and have demonstrated promising activity in pediatric gliomas (17–22). The gene discussed is MAP2K1; the disease is central nervous system cancer.